Noxopharm talks partnership with Hudson Institute of Medical Research
October 12, 2023 at 11:11 am EDT
Share
(via NewsDirect)
Noxopharm Ltd (ASX:NOX, OTC:NOXOF) chief executive officer Dr Gisela Mautner joins Proactive alongside Associate Professor Michael Gantier from the Hudson Institute of Medical Research to discuss their partnering on the SOF-VAC mRNA vaccine enhancer. They’re investigating the potential for Sofra oligonucleotides to limit the inflammatory side effects associated with mRNA therapeutics and vaccines. They say the ability of the oligonucleotides to reduce inflammation opens up new possibilities for the treatment of many diseases.
Noxopharm is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines.
It has three active drug development programs: two innovative technology platforms – Sofra™ (mRNA vaccines, inflammation and autoimmunity) and Chroma™ (oncology) which provide the basis for active development of a growing pipeline of new proprietary drugs, as well as its clinical drug candidate Veyonda®.
The company has unique proprietary technology aimed at making mRNA vaccines safer to take by reducing side effects while reducing manufacturing costs for vaccine producers.
Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.
NOXOPHARM LIMITED 
